证券记录 · 已归档季度
BMRN
BioMarin Pharmaceutical Inc. · Healthcare · Biotechnology
21被追踪持有人
0Δ持有人
70.58M持有股份
$4.99B报告持仓市值
+1新建仓位
−1清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +4.1% · 净新建仓位 0.0% — 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 137 | +4 | 147.00M | $8.41B | +11 | −6 |
| Q1 2026 | 135 | -4 | 142.18M | $8.03B | +5 | −10 |
| Q4 2025 | 138 | +3 | 154.93M | $9.20B | +4 | — |
| Q3 2025 | 23 | -1 | 108.93M | $5.90B | — | −2 |
| Q2 2025 | 22 | -2 | 113.78M | $6.25B | — | −2 |
| Q1 2025 | 21 | 0 | 70.58M | $4.99B | +1 | −1 |
| Q4 2024 | 21 | +1 | 67.83M | $4.46B | +1 | — |
| Q3 2024 | 19 | 0 | 57.19M | $4.02B | +2 | −2 |
| Q2 2024 | 19 | — | 53.80M | $4.43B | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 17.77M | -2.3% | $1.26B | 1.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Dodge & Cox ✦ | 14.96M | +1.4% | $1.06B | 0.6% | ▲ Add | 4 | SEC ↗ |
| 3 | Viking Global Investors ✦ | 10.80M | +2.8% | $763.46M | 2.4% | ▲ Add | 4 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (被动) | 8.46M | -7.1% | $598.26M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Elliott Investment Management ✦ | 3.50M | 0.0% | $247.44M | 2.3% | Held | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (被动) | 3.43M | +4.3% | $242.02M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (被动) | 3.31M | -7.3% | $233.87M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 2.93M | +127.9% | $203.99M | 0.2% | ▲ Add | 4 | SEC ↗ ×7 |
| 9 | Citadel Advisors ✦ | 1.60M | +311.5% | $112.75M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 895.77K | +105.5% | $63.32M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 759.39K | +226.2% | $53.68M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 12 | Millennium Management ✦ | 675.27K | +65.4% | $47.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 545.77K | +98.1% | $38.58M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 395.75K | +48.5% | $27.98M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 218.07K | 新增 | $15.42M | 0.0% | New | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 132.35K | -77.7% | $9.36M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 17 | Bridgewater Associates ✦ | 123.66K | -59.1% | $8.74M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 47.47K | +304.5% | $3.36M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Marshall Wace ✦ | 14.34K | -97.9% | $1.01M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 13.57K | -2.8% | $959,538 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | GAMCO Investors ✦ | 8.29K | -17.4% | $586,020 | 0.0% | ▼ Trim | 4 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Arrowstreet Capital | $15.42M | 0.0% |
已清仓
| Wellington Management | $490,412 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 549 持有人, 183.01M 股份, $10.09B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 02
Davis George Eric
Officer · 17.56K 股 · $1.16M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据